

Art Unit: 1626

CLMPTO

KD

01/21/05

CLAIMS 1-53 CANCELED

54. A method for inhibiting LT- β -R signalling without inhibiting TNF-R signalling comprising the step of administering to a subject an effective amount of a LT- β -R blocking agent.

55. The method according to claim 54, wherein the LT- β -R blocking agent is selected from the group consisting of a soluble lymphotoxin- β receptor, an antibody directed against LT- β receptor, and an antibody directed against surface LT ligand.

56. The method according to claim 54, wherein the subject comprises one or more cells from a mammal.

Art Unit: 1626

- 63 -

57. The method according to claim 56, wherein the mammal is a human.

58. The method according to claim 54, wherein the LT- β -R blocking agent comprises a soluble lymphotoxin- β receptor having a ligand binding domain that can selectively bind to a surface LT ligand.

59. The method according to claim 58, wherein the soluble lymphotoxin- β receptor further comprises a human immunoglobulin Fc domain.

60. The method according to claim 54, wherein the LT- β -R blocking agent comprises a monoclonal antibody directed against LT- β receptor.

61. The method according to claim 57, wherein the LT- β -R blocking agent comprises anti-human LT- β -R mAb BDA8.

62. The method according to claim 54, wherein the LT- β -R blocking agent comprises a monoclonal antibody directed against surface LT ligand.

63. The method according to claim 62, wherein the antibody is directed against a subunit of the LT ligand.

64. The method according to claim 57, wherein the LT- β -R blocking agent comprises anti-human LT- β mAb B9.

65. The method according to claim 56, wherein the mammal is a mouse and the LT- β -R blocking agent comprises a monoclonal antibody directed against a murine surface LT ligand.

66. The method according to claims 60, wherein the LT- β -R blocking agent is administered in an amount sufficient to coat LT- β receptor-positive cells for 1 to 14 days.

--

67. The method according to claims 62, wherein the LT- β -R blocking agent is administered in an amount sufficient to coat surface LT ligand-positive cells for 1 to 14 days.

CLAIMS 68-69 CANCELED